<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39154292</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>221</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med J Aust</ISOAbbreviation></Journal><ArticleTitle>The public health and economic burden of long COVID in Australia, 2022-24: a modelling study.</ArticleTitle><Pagination><StartPage>217</StartPage><EndPage>223</EndPage><MedlinePgn>217-223</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5694/mja2.52400</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To estimate the number of people in Australia with long COVID by age group, and the associated medium term productivity and economic losses.</AbstractText><AbstractText Label="STUDY DESIGN">Modelling study: a susceptible-exposed-infected-recovered (SEIR) model to estimate the number of people with long COVID over time following single infections, and a labour supply model to estimate productivity losses as a proportion of gross domestic product (GDP).</AbstractText><AbstractText Label="SETTING">Australia, 2022-2024.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Estimated number of people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during 2022-2023 (based on serosurvey data) who have long&#xa0;COVID, 2022-2024, by age group; estimated GDP loss during 2022 caused by reduced labour supply attributable to long COVID.</AbstractText><AbstractText Label="RESULTS">Our model projected that the number of people with long COVID following a single infection in 2022 would peak in September 2022, when 310&#x2009;341-1&#x2009;374&#x2009;805 people (1.2-5.4% of Australians) would have symptoms of long COVID, declining to 172&#x2009;530-872&#x2009;799 people (0.7-3.4%) in December 2024, including 7902-30&#x2009;002 children aged 0-4 years (0.6-2.2%). The estimated mean labour loss attributable to long COVID in 2022 was projected to be 102.4&#xa0;million (95% confidence interval [CI], 50.4-162.2 million) worked hours, equivalent to 0.48% (95% CI, 0.24-0.76%) of total worked hours in Australia during the 2020-21 financial year. The estimated mean GDP loss caused by the projected decline in labour supply and reduced use of other production factors was $9.6 billion (95% CI, $4.7-15.2 billion), or 0.5% of GDP. The estimated labour loss was greatest for people aged 30-39 years (27.5 million [95% CI, 16.0-41.0 million] hours; 26.9% of total labour loss) and people aged 40-49 years (24.5 million [95% CI, 12.1-38.7 million] hours; 23.9% of total labour loss).</AbstractText><AbstractText Label="CONCLUSION">Widespread SARS-CoV-2 infections in Australia mean that even a small proportion of infected people developing long COVID-related illness and disability could have important population health and economic effects. A paradigm shift is needed, from a sole focus on the immediate effects of coronavirus disease 2019 (COVID-19) to preventing and treating COVID-19 and treating long COVID, with implications for vaccine and antiviral policy and other mitigation of COVID-19.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s). Medical Journal of Australia published by John Wiley &amp; Sons Australia, Ltd on behalf of AMPCo Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Costantino</LastName><ForeName>Valentina</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-6017-4430</Identifier><AffiliationInfo><Affiliation>The Kirby Institute, Sydney, NSW.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grafton</LastName><ForeName>Quentin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Crawford School of Public Policy, Australian National University, Canberra, ACT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kompas</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Centre of Excellence for Biosecurity Risk Analysis, University of Melbourne, Melbourne, VIC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chu</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Crawford School of Public Policy, Australian National University, Canberra, ACT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honeyman</LastName><ForeName>Damian</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Kirby Institute, Sydney, NSW.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Notaras</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Kirby Institute, Sydney, NSW.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacIntyre</LastName><ForeName>C Raina</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>The Kirby Institute, Sydney, NSW.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>#2016907</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant><Grant><Agency>Balvi Filantropik fund</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017281" MajorTopicYN="Y">Cost of Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059066" MajorTopicYN="N">Gross Domestic Product</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>18</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>18</Day><Hour>10</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39154292</ArticleId><ArticleId IdType="doi">10.5694/mja2.52400</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thaweethai T, Jolley SE, Karlson EW, et&#xa0;al; RECOVER Consortium. Development of a definition of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection. JAMA 2023; 329: 1934&#x2010;1946.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID basics. Updated 11 June 2024. https://www.cdc.gov/covid/long&#x2010;term&#x2010;effects/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019&#x2010;ncov/long&#x2010;term&#x2010;effects (viewed June 2024).</Citation></Reference><Reference><Citation>World Health Organization. Post COVID&#x2010;19 condition (long COVID). 7 Dec 2022. https://www.who.int/europe/news&#x2010;room/fact&#x2010;sheets/item/post&#x2010;COVID&#x2010;19&#x2010;condition (viewed Nov 2023).</Citation></Reference><Reference><Citation>National Institute for Health and Care Excellence. COVID&#x2010;19 rapid guideline: managing the long&#x2010;term effects of COVID&#x2010;19 [NG188]. Updated 25 Jan 2024. https://www.who.int/docs/default&#x2010;source/immunization/sage/covid/sage&#x2010;prioritization&#x2010;roadmap&#x2010;covid19&#x2010;vaccines.pdf?Status=Temp&amp;sfvrsn=bf227443_2 (viewed June 2024).</Citation></Reference><Reference><Citation>Munblit D, Nicholson TR, Needham DM, et&#xa0;al. Studying the post&#x2010;COVID&#x2010;19 condition: research challenges, strategies, and importance of Core Outcome Set development. BMC Med 2022; 20: 50.</Citation></Reference><Reference><Citation>Bull&#x2010;Otterson L, Baca S, Saydah S, et&#xa0;al. Post&#x2010;COVID conditions among adult COVID&#x2010;19 survivors aged 18&#x2013;64 and &#x2265; 65 years: United States, March 2020&#x2013;November 2021. MMWR Morb Mortal Wkly Rep 2022; 71: 713&#x2010;717.</Citation></Reference><Reference><Citation>Lopez&#x2010;Leon S, Wegman&#x2010;Ostrosky T, Ayuzo del Valle NC, et&#xa0;al. Long&#x2010;COVID in children and adolescents: a systematic review and meta&#x2010;analyses. Sci Rep 2022; 12: 9950.</Citation></Reference><Reference><Citation>Adler L, Gazit S, Pinto Y, et&#xa0;al. Long&#x2010;COVID in patients with a history of mild or asymptomatic SARS&#x2010;CoV&#x2010;2 infection: a nationwide cohort study. Scand J Prim Health Care 2022; 40: 342&#x2010;349.</Citation></Reference><Reference><Citation>Ma Y, Deng J, Liu Q, et&#xa0;al. Long&#x2010;term consequences of asymptomatic SARS&#x2010;CoV&#x2010;2 infection: a systematic review and meta&#x2010;analysis. Int J Environ Res Public Health 2023; 20: 1613.</Citation></Reference><Reference><Citation>Bowe B, Xie Y, Al&#x2010;Aly Z. Acute and postacute sequelae associated with SARS&#x2010;CoV&#x2010;2 reinfection. Nat Med 2022; 28: 2398&#x2010;2405.</Citation></Reference><Reference><Citation>Azzolini E, Levi R, Sarti R, et&#xa0;al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in&#xa0;health care workers. JAMA 2022; 328: 676&#x2010;678.</Citation></Reference><Reference><Citation>Tran V, Perrodeau E, Saldanha J, et&#xa0;al. Efficacy of first dose of covid&#x2010;19 vaccine versus no vaccination on symptoms of patients with long covid: target trial emulation based on ComPaRe e&#x2010;cohort. BMJ Med 2023; 2: e000229.</Citation></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et&#xa0;al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. eClinicalMedicine 2021; 38: 101019.</Citation></Reference><Reference><Citation>Trades Union Congress (United Kingdom). Workers&#x2019; experience of Long Covid. Joint report by the TUC and Long Covid Support. 27 Mar 2023. https://www.tuc.org.uk/research&#x2010;analysis/reports/workers&#x2010;experience&#x2010;long&#x2010;covid (viewed July 2024).</Citation></Reference><Reference><Citation>World Health Organization. WHO SAGE Roadmap for prioritizing uses of COVID&#x2010;19 vaccines. 10 Dec 2023. https://www.who.int/docs/default&#x2010;source/immunization/sage/covid/sage&#x2010;prioritization&#x2010;roadmap&#x2010;covid19&#x2010;vaccines.pdf?Status=Temp&amp;sfvrsn=bf227443_2 (viewed May 2023).</Citation></Reference><Reference><Citation>Syed A, O'Connor P. Australian state governments and mandatory reporting of positive COVID tests as a new surge begins. World Socialist Web Site, 1 Nov 2022. https://www.wsws.org/en/articles/2022/11/02/xssk&#x2010;n02.html (viewed July 2024).</Citation></Reference><Reference><Citation>Giattino C. How epidemiological models of COVID&#x2010;19 help us estimate the true number of infections. Our World in Data, 24 Aug 2020. https://ourworldindata.org/covid&#x2010;models (viewed Nov 2022).</Citation></Reference><Reference><Citation>Hoz&#xe9; N, Paireau J, Lapidus N, et&#xa0;al. Monitoring the proportion of the population infected by SARS&#x2010;CoV&#x2010;2 using age&#x2010;stratified hospitalisation and serological data: a modelling study. Lancet Public Health 2021; 6: e408&#x2010;e415.</Citation></Reference><Reference><Citation>Oran DP, Topol EJ. Prevalence of asymptomatic SARS&#x2010;CoV&#x2010;2 infection: a narrative review. Ann Intern Med 2020; 173: 362&#x2010;367.</Citation></Reference><Reference><Citation>Oran DP, Topol EJ. The proportion of SARS&#x2010;CoV&#x2010;2 infections that are asymptomatic: a systematic review. Ann Intern Med 2021; 174: 655&#x2010;662.</Citation></Reference><Reference><Citation>Kirby Institute. Serosurveillance for SARS&#x2010;CoV&#x2010;2 infection to inform public health responses. Undated. https://kirby.unsw.edu.au/project/serosurveillance&#x2010;sars&#x2010;cov&#x2010;2&#x2010;infection&#x2010;inform&#x2010;public&#x2010;health&#x2010;responses (viewed Nov 2022).</Citation></Reference><Reference><Citation>Paediatric Active Enhanced Disease Surveillance. Paediatric SARS&#x2010;CoV&#x2010;2 serosurvey 2022, Australia. Summary report. 3 Nov 2022. https://paeds.org.au/sites/default/files/2022&#x2010;11/PAEDS%20NCIRS_COVID&#x2010;19%20Paediatric%20Serosurvey%202022%20Report_3&#x2010;11&#x2010;2022_Final_1.pdf (viewed Nov 2022).</Citation></Reference><Reference><Citation>Liu Y, Rockl&#xf6;v J. The effective reproductive number of the Omicron variant of SARS&#x2010;CoV&#x2010;2 is several times relative to Delta. J Travel Med 2022; 29: taac037.</Citation></Reference><Reference><Citation>World Health Organization. Consultation on the development of guidance on how to incorporate the results of modelling into WHO guidelines Geneva, Switzerland, 27&#x2013;29 April 2016. https://iris.who.int/bitstream/handle/10665/258987/WHO&#x2010;HIS&#x2010;IER&#x2010;REK&#x2010;2017.2&#x2010;eng.pdf (viewed Mar 2024).</Citation></Reference><Reference><Citation>Ertesv&#xe5;g NU, Iversen A, Blomberg B, et&#xa0;al; Bergen COVID&#x2010;19 research group. Post COVID&#x2010;19 condition after delta infection and omicron reinfection in children and adolescents. eBioMedicine 2023; 92: 104599.</Citation></Reference><Reference><Citation>Australian Bureau of Statistics. Australian national accounts: input&#x2013;output tables, 2020&#x2013;21; here: Table&#xa0;5. 30 Mar 2023. https://www.abs.gov.au/statistics/economy/national&#x2010;accounts/australian&#x2010;national&#x2010;accounts&#x2010;input&#x2010;output&#x2010;tables/2020&#x2010;21/5209055001DO001_202021.xlsx (viewed June 2023).</Citation></Reference><Reference><Citation>Peter RS, Nieters A, Kr&#xe4;usslich HG, et&#xa0;al; EPILOC Phase 1 Study Group. Post&#x2010;acute sequelae of covid&#x2010;19 six to 12 months after infection: population based study. BMJ 2022; 379 e071050.</Citation></Reference><Reference><Citation>Australian Bureau of Statistics. Australian national accounts: national income, expenditure and product. Table&#xa0;1. 2024. https://www.abs.gov.au/statistics/economy/national&#x2010;accounts/australian&#x2010;national&#x2010;accounts&#x2010;national&#x2010;income&#x2010;expenditure&#x2010;and&#x2010;product/mar&#x2010;2024/5206001_Key_Aggregates.xlsx (viewed July 2024).</Citation></Reference><Reference><Citation>Janda M. Australia's economy grew 0.5pc in December 2022 quarter, ABS data reveal, well below most economists' forecasts. ABC News (Australia), 1 Mar 2023. https://www.abc.net.au/news/2023&#x2010;03&#x2010;01/australian&#x2010;gdp&#x2010;december&#x2010;2022&#x2010;abs&#x2010;economic&#x2010;growth&#x2010;slowing/102038014 (viewed June 2023).</Citation></Reference><Reference><Citation>Australian Institute of Health and Welfare. Heart, stroke and vascular disease: Australian facts. Updated 30 June 2023. Archived: https://web.archive.org/web/20230928063950/https://www.aihw.gov.au/reports/heart&#x2010;stroke&#x2010;vascular&#x2010;diseases/hsvd&#x2010;facts/contents/disease&#x2010;types (viewed June 2023).</Citation></Reference><Reference><Citation>Office for National Statistics. Self&#x2010;reported long COVID and labour market outcomes, UK: 2022. 5&#xa0;Dec 2022. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidandlabourmarketoutcomesuk2022/selfreportedlongcovidandlabourmarketoutcomesuk2022 (viewed Nov 2023).</Citation></Reference><Reference><Citation>Hensher M, Angeles MR. Potential scale of long COVID cases from the Omicron wave in&#xa0;Australia: summer 2021&#x2013;2022 [briefing paper]. Geelong: Institute for Health Transformation, Deakin University, 2022. https://iht.deakin.edu.au/wp&#x2010;content/uploads/sites/153/2022/02/Long&#x2010;COVID&#x2010;Omicron&#x2010;briefing&#x2010;paper&#x2010;IHT&#x2010;02&#x2010;2022.pdf (viewed Nov 2023).</Citation></Reference><Reference><Citation>Byambasuren O, Stehlik P, Clark J, et&#xa0;al. Effect of covid&#x2010;19 vaccination on long covid: systematic review. BMJ Med 2023; 2: e000385.</Citation></Reference><Reference><Citation>Xie Y, Choi T, Al&#x2010;Aly Z. Association of treatment with nirmatrelvir and the risk of post&#x2010;COVID&#x2010;19 condition. JAMA Intern Med 2023; 183: 554&#x2010;564.</Citation></Reference><Reference><Citation>Australian Technical Advisory Group on Immunisation. Statement on the administration of COVID&#x2010;19 vaccines in 2024. 29 Feb 2024. https://www.health.gov.au/sites/default/files/2024&#x2010;03/atagi&#x2010;statement&#x2010;on&#x2010;the&#x2010;administration&#x2010;of&#x2010;covid&#x2010;19&#x2010;vaccines&#x2010;in&#x2010;2024.pdf (viewed July 2024).</Citation></Reference><Reference><Citation>Kikkenborg Berg S, Palm P, Nygaard U, et&#xa0;al. Long COVID symptoms in SARS&#x2010;CoV&#x2010;2&#x2010;positive children aged 0&#x2013;14 years and matched controls in Denmark (LongCOVIDKidsDK): a national, cross&#x2010;sectional study. Lancet Child Adolesc Health 2022; 6: 614&#x2010;623.</Citation></Reference><Reference><Citation>Guo Y, Dou Z, Zhang N, et&#xa0;al. Student close contact behavior and COVID&#x2010;19 transmission in China's classrooms. PNAS Nexus 2023; 2: pgad200.</Citation></Reference><Reference><Citation>Suran M. Studies investigate whether antivirals like paxlovid may prevent long COVID. JAMA 2024; 331: 98&#x2010;100.</Citation></Reference><Reference><Citation>Yang C, Zhao H, Esp&#xed;n E, Tebbutt SJ. Association of SARS&#x2010;CoV&#x2010;2 infection and persistence with long COVID. Lancet Respir Med 2023; 11: 504&#x2010;506.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>